Novo Nordisk's Regulatory Headaches Pile Up as Buyback Support Faces Its Toughest Test

Novo Nordisk hit by a fourth Danish legal breach, three over LinkedIn weight-loss ads, as shares fall 23% and the FDA extends its Denecimig review.

Danish authorities have flagged a fourth legal breach by Novo Nordisk this year, with three of the violations involving unlawful direct-to-consumer advertising of weight-loss treatments on LinkedIn. The findings, first reported in the Danish media, land as the drugmaker navigates a bruising stretch on its home turf, where regulations flatly prohibit consumer-facing promotion of prescription medicines.

The rebuke is not an isolated one. On September 28, Denmark's pharmaceutical industry ethics board imposed a fine of DKK 45,000 plus VAT on Novo Nordisk over a joint patient-support program for Wegovy run with service provider Falck, ordering the arrangement to be wound down in its existing form. Novo Nordisk subsequently ended the partnership, according to media reports, while making clear it disagreed with the ethics council's ruling.

Analysts Trim Targets as the Stock Sits Deep in the Red

The regulatory friction coincides with a market environment that has already turned unforgiving. Shares closed Tuesday at EUR 33.97, leaving the stock down 23% since the start of the year. Ahead of the open, the paper was quoted at EUR 33.83.

Brokerages have been adjusting their expectations accordingly. Danske Bank cut its price target to DKK 345 from DKK 365 on Wednesday while keeping a "Buy" rating. Deutsche Bank, by contrast, maintained its "Sell" stance and lowered its target to DKK 225 from DKK 245, citing slightly negative read-throughs from data presented at the EASD diabetes conference.

Buyback Engine Keeps Humming

Against that backdrop, Novo Nordisk continues to lean on its share repurchase program as a defensive tool. The company disclosed Monday the acquisition of 1,225,000 B shares between September 28 and October 2, a tranche worth DKK 307.4 million. The purchases form part of a broader buyback framework with a total ceiling of DKK 15 billion.

Since February 4, the group has repurchased 36,604,179 B shares for a cumulative DKK 10,247,270,869 — meaning the lion's share of the authorized program has already been executed. Management's stated aim is to optimize the capital structure and shore up value for existing shareholders, while the shrinking free float serves as a visible demonstration of financial firepower.

FDA Delay Puts Denecimig's Timeline in the Spotlight

The more consequential question for Novo Nordisk's trajectory concerns operational reliability at its manufacturing sites. Roughly a week ago, the U.S. Food and Drug Administration extended its regulatory review of Denecimig, a treatment for hemophilia A, because of ongoing remediation work at a production facility.

The agency did not attach a new decision date, leaving market participants in a holding pattern. Importantly, the FDA identified no deficiencies in clinical efficacy or safety data — the holdup stems from technical adjustments and follow-up inspections at the plant. How long those processes take will determine when the product can reach the U.S. market.

Novo Nordisk has stressed that the Denecimig extension carries no implications for its financial outlook for the 2026 fiscal year. Should approval come through once remediation is complete, the company is targeting a U.S. launch in the first half of 2027.

A Binary Setup Heading Into 2027

That first-half 2027 window now functions as the pivotal waypoint. If Novo Nordisk defends its 2026 guidance and clears the manufacturing corrections without further objections, the existing buyback program should provide a buffer against deeper declines. Should the U.S. timeline slip on additional supervisory demands, however, the downtrend could gather pace.

The next major catalyst is the FDA's verdict on Denecimig ahead of the targeted launch. Investors must now weigh whether the defensive support from the company's own share purchases is enough to offset the operational risks until a final decision lands — with the added complication that Danish regulators have shown little appetite for leniency on the marketing side.